104 results on '"Hubbard, R C"'
Search Results
2. Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia†
3. Analgesic Efficacy and Plasma Levels of a Highly Selective Inhibitor of COX-2 (SC-58635;SC) in Patients with Post-Surgical Dental Pain: PIII-2
4. Reduced Incidence of Gastroduodenal Ulcers With Celecoxib, A Novel Cyclooxygenase-2 Inhibitor, Compared To Naproxen in Patients With Arthritis
5. Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid
6. Intravenous recombinant secretory leukoprotease inhibitor augments antineutrophil elastase defense
7. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages.
8. Expression of the secretory leukoprotease inhibitor gene in epithelial cells.
9. Risk factors for emphysema. Cigarette smoking is associated with a reduction in the association rate constant of lung alpha 1-antitrypsin for neutrophil elastase.
10. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor.
11. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium
12. Antioxidant macromolecules in the epithelial lining fluid of the normal human lower respiratory tract.
13. Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosol.
14. Molecular basis of alpha 1-antitrypsin deficiency and emphysema associated with the alpha 1-antitrypsin Mmineral springs allele.
15. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial.
16. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
17. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin.
18. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo
19. A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model
20. Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance.
21. Biochemical Efficacy and Safety of Monthly Augmentation Therapy for α1-Antitrypsin Deficiency
22. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis.
23. Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase.
24. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis.
25. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency.
26. Normal alveolar epithelial lining fluid contains high levels of glutathione
27. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency
28. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase.
29. The Straight Line Developing Machine
30. Committee Activities: Report of the Sound Committee
31. Report of Standards and Nomenclature Committee
32. Parecoxib sodium demonstrates opioid sparing effects in post-laparotomy surgical patients.
33. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.
34. The analgesic efficacy of intramuscular parecoxib sodium in postoperative dental pain.
35. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip.
36. A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects.
37. The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively.
38. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee.
39. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
40. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects.
41. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial.
42. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial.
43. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
44. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
45. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
46. Conversion from twice- to once-daily extended-release theophylline treatment in patients with reversible airway obstruction.
47. Legalize drugs.
48. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis.
49. Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E.
50. Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.